339 related articles for article (PubMed ID: 32691891)
21. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
[TBL] [Abstract][Full Text] [Related]
22. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
23. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
Kollipara S; Ahmed T; Praveen S
Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
[TBL] [Abstract][Full Text] [Related]
24. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
[TBL] [Abstract][Full Text] [Related]
25. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
26. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
27. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
[TBL] [Abstract][Full Text] [Related]
28. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
29. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
30. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects.
Aslanis V; Umehara K; Huth F; Ouatas T; Bharathy S; Butler AA; Zhou W; Gadbaw B
Cancer Chemother Pharmacol; 2019 Oct; 84(4):749-757. PubMed ID: 31324935
[TBL] [Abstract][Full Text] [Related]
31. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
[TBL] [Abstract][Full Text] [Related]
32. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
33. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
[TBL] [Abstract][Full Text] [Related]
34. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
[TBL] [Abstract][Full Text] [Related]
35. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
[TBL] [Abstract][Full Text] [Related]
36. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
37. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385
[TBL] [Abstract][Full Text] [Related]
38. Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin.
Kapetas AJ; Abuhelwa AY; Sorich MJ; McKinnon RA; Rodrigues AD; Rowland A; Hopkins AM
AAPS J; 2021 Aug; 23(5):104. PubMed ID: 34467456
[TBL] [Abstract][Full Text] [Related]
39. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates.
Ramsden D; Fung C; Hariparsad N; Kenny JR; Mohutsky M; Parrott NJ; Robertson S; Tweedie DJ
Drug Metab Dispos; 2019 Oct; 47(10):1206-1221. PubMed ID: 31439574
[TBL] [Abstract][Full Text] [Related]
40. Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.
Jia G; Ren C; Wang H; Fan C
BMC Pharmacol Toxicol; 2024 Jan; 25(1):4. PubMed ID: 38167223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]